Aims: Antibody-labelled gold nanoparticles represent an attractive tool for cancer imaging and therapy.
Immunotargeted gold nanomaterials represent an attractive tool for cancer imaging and treatment [1] . During the past decade, the biomedical use of gold nanoparticles (AuNPs) has piqued in interest owing to their good biocompatibility and their interesting optical properties, which can be used to improve the management of cancer [2] . Recently, promising applications of AuN-P-based systems as contrast agents for cancer imaging [3] or therapeutic agents for photothermal therapy have been reported [4] . Interestingly, AuNPs can be easily modified with various ligands, including specific monoclonal antibodies (mAbs). Functionalization of AuNP surfaces with mAbs enables them to have an adequate biodistribution as well as specifically target and be accumulated in cells that express or overexpress a specific surface membrane antigen. Thus, the resulting gold immunonanoconjugates are expected to be a good strategy for enhancing the efficacy of tumor targeting while reducing toxicity in normal tissues [5] .
In this study, we functionalized AuNPs by choosing mAbs directed against endoglin (CD105), a homodimeric cell surface glycoprotein that is overexpressed on angiogenic vascular endothelial cells [6] [7] [8] [9] [10] [11] [12] [13] and in some cancer cells, such as melanoma [14, 15] and choriocarcinoma cells [16] . Furthermore, the vascular density of CD105, determined using anti-CD105 mAbs, is correlated with tumor prognosis [17] , the risk of developing metastatic disease [18] and the recurrence of malignancy [19] . Recently, several studies have indicated that CD105 represents a more specific and sensitive marker for tumor angiogenesis and tumor progression than the commonly used pan-endothelial markers, such as CD34 and CD31, in various types of human malignancies [17, [20] [21] [22] . Thus, CD105 targeting has been used as an antiangiogenic therapy based on attacking both the tumor neovasculature as well as cancer cells that overexpress CD105 [23] . Nevertheless, tumors may still become resistant to antiangiogenic therapy [24] . Preclinical studies indicate that combining these agents with conventional cytotoxic agents or radiation therapy results in an additive or even synergistic antitumor effect [25] .
Other approaches are to provide immunoconjugates with either immunotoxins or radioantibodies, which are effective for suppression of tumor growth [26] [27] [28] [29] [30] [31] and metastasis [32] . Although anti-endoglin mAbs are successfully used as intrinsic therapeutic agents, they can also be used as targeting agents. Within this context, antibody-targeted AuNPs may represent an interesting combined approach for improving the efficacy of the standard inhibitors of angiogenesis thanks to the photophysical properties of AuNPs.
The main goal of this work is to characterize the impact of nanoparticle conjugation reactions on the target recognition properties of anti-CD105 mAbs in vitro and in vivo. Recently, we described the synthesis and characterization of cetuximab-targeted AuNPs. We investigated the impact of nanoparticle conjugation on cetuximab biodistribution and tumor targeting through an ex vivo biodistribution study [33] and in vivo noninvasive PET imaging [34] . We demonstrated that the conjugation of cetuximab to AuNPs did not significantly affect EGFR-dependent tumor uptake in mice. The present study was designed to assess the in vivo distribution of anti-endoglin mAbs conjugated to AuNPs compared to that of unconjugated mAbs, and to explore the effect of nanoparticle conjugation on tumor targeting. To trace these immuno conjugates, anti-CD105 mAbs were radiolabelled in advance using zirconium-89 ( 89 Zr). 89 Zr has an ideal long physical half-life (78.41 h) for PET imaging [35] of intact mAbs, which require time (typically 2-4 days) to reach optimal biodistribution and tumor targeting [36] .
Materials & methods
Production & characterization of 89 Zr-labelled anti-CD105 mAbs 89 Zr was produced and purified in-house, as previously described [34, 37, 38] . The rat anti-mouse CD105 mAb was produced from a hybridoma (clone MJ7/18), which was provided by the Developmental Studies Hybridoma Bank (Iowa University, IA, USA). 89 Zr-labelled anti-CD105 mAbs ( 89 Zr-Df-Bz-NCS-anti-CD105) was prepared according to a protocol described previously [39, 40] . First, the antibody was purified by protein G-affinity chromatography and dialysis into phosphate-buffered saline (PBS; 140 mM NaCl, 6 mM Na 2 HPO 4 , 3 mM KCl, 1 mM KH 2 PO 4 , pH 7.2) follow ed by size-exclusion chromatography on a Superdex 200 column (GE Healthcare Life Sciences, Belgium) using a 20 mM TRIS-HCl buffer (pH 7.5) containing 0.15 M NaCl. Then, the purified mAbs were functionalized with the bifunctional chelating agent p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS; Macrocyclics, TX, USA), as previously described [34] . Finally, the functionalized antibody (Df-Bz-NCS-anti-CD105) was purified by size exclusion chromatography using a PD10 column (GE Healthcare Life Sciences, Belgium) and radiolabelled with the produced 89 Zr-oxalate (74-111 MBq).
The radiochemical yield and purity were determined by using instant thin-layer chromatography (ITLC) and 20 mM citric acid (pH 4.9-5.1) as the mobile phase. ITLC migration was followed by radio-TLC detection (Mini-Gita TLC scanner, Raytest, Germany), which showed that the radiolabelled antibody migrated with Rf < 0.1, whereas unbound 89 Zr migrated to the solvent front. In addition, the integrity of the antibody after radiolabelling was checked by 10% SDS-PAGE gel (under nonreducing conditions) followed by radio-TLC detection (Bioscan system 200 imaging scanner), or by gel scanning using Phosphor Imager (Fujifilm FLA-5100) ana lysis.
Synthesis & characterization of 89 Zr-labelled anti-CD105 mAbs conjugated to AuNPs AuNPs were synthesized and coated with plasma-polymerized allylamine (PPAA) through a physical vapor deposition technique (PVD), as previously described by our group [41] . The coated nanoparticles (AuNPs-PPAA) were purified as previously reported [33] . Anti-CD105 mAbs were conjugated to AuNPs-PPAA using carbodiimide chemistry and purified as previously described in our latest works [33] [34] . The efficiency of the conjugation reaction between AuNPs-PPAA and 89 Zr-labelled anti-CD105 mAbs was assessed using 10% SDS-PAGE gel (under nonreducing conditions), followed by a radio-TLC ana lysis.
Physicochemical characterizations of AuNPs-PPAA and the immunonanoconjugates were performed as previously detailed [33, 34, 41, 42] . In brief, TEM (Philips Tecnai 10 transmission electron microscope) was carried out to assess the morphology and size distribution of AuNPs-PPAA. Differential centrifugal sedimentation (DCS; DC 24000 Disk Centrifuge; CPS Instruments, Inc., FL, USA) was performed to determine the size of 89 Zr-labelled mAbs conjugated to AuNPs ( 89 Zr-anti-CD105-AuNPs-PPAA) by measuring the time required for these immunonanoconjugates to traverse a sucrose density gradient created in a disk centrifuge. This method used calibrated AuNPs coated layer by layer with polyelectrolytes to estimate the size of the tracer [33] .
A mouse melanoma cell line (B16F10-luc) and embryonic endothelial progenitor cells (eEPC) were maintained in alpha minimum essential medium (MEM-alpha with glutamine, Gibco-Invitrogen, Belgium) supplemented with 10% heat-inactivated foetal bovine serum (FBS, Gibco-Invitrogen, Belgium), 1% streptomycin-penicillin (Gibco-Invitrogen, Belgium) and 1% MEM nonessential amino acids (Gibco-Invitrogen, Belgium), or in Dulbecco's modified Eagle's medium (DMEM glucose 4.5 g l -1 without pyruvate, Gibco-Invitrogen, Belgium), supplemented with 10% fetal bovine serum and 1% streptomycin-penicillin respectively.
B16F10-luc or eEPC cells (10 4 cells per well) were grown in 96-well plates (Thermo Fisher Scientific, Belgium) 24 h prior to the ELISA test. Cells were washed once with PBS for cell culture (Lonza, Belgium), then fixed for a 10-min strict with PBS-containing 4% paraformaldehyde. After one wash with PBS, wells were blocked with 5% non-fat dry milk in PBS for 1 h at room temperature. Cells were rinsed twice with PBS and once with PBS containing 1% BSA (1% BSA-PBS) for 5 min. Anti-CD105 mAbs and anti-CD105-AuNPs-PPAA were added to the cells at various concentrations for 1 h at room temperature. Wells were washed six times with 1% BSA-PBS. Then, goat antirat IgG conjugated to peroxidase (Jackson Immunoresearch Laboratories, Belgium) diluted in 1% BSA-PBS at 0.32 mg ml -1 was added for 30 min at room temperature. After three washing steps with 1% BSA-PBS, the enzyme activity was revealed by adding 100 µl of TMB substrate (Merck Chemicals, Belgium) to each well for 20 min in the dark. The reaction was stopped with 250 mM HCl and the cell binding was quantified spectrophotometrically at 450 nm.
In vitro stability of radioimmunoconjugates in plasma
The in vitro stability of both purified 89 Zr-Df-Bz-NCS-anti-CD105 and 89 Zr-anti-CD105-AuNPs-P-PAA was studied in fresh mouse plasma by incubating the solution of radiolabelled mAbs (1:2 v/v dilution at a final concentration of 1.1 MBq ml -1 ; sodium azide added at 0.02%) at 37°C with stirring. At different times after incubation (6, 24, 48 and 72 h), aliquots of plasma (10 µl) were analyzed using radio-ITLC.
Comparative biodistribution studies in mice using animal PET/CT imaging For the biodistribution assessment using PET imaging, C57BL/6J male mice (22-26 g, 5-6 weeks old; Janvier, France) bearing melanoma xenografts were used. The mice were inoculated subcutaneously in the flanks with 1 × 10 6 B16F10-luc cells (one or two tumors per mouse). After approximately 10 days, the diameter of the tumors had reached 7.5-8.5 mm and the mice were ready for in vivo experiments. All animal experiments were conducted in accordance with national and university animal care regulations.
To compare the pharmacokinetic profiles of native radiolabelled mAbs and those conjugated to AuNPs, two groups of three to five mice were injected intravenously in the lateral tail vein with either freshly prepared 89 Zr-Df-Bz-NCS-anti-CD105 or with 89 Zranti-CD105-AuNPs-PPAA (2.9-4.1 MBq; total of 350-400 µg mAbs per mouse). In addition, to assess the in vivo specificity of anti-CD105 mAbs conjugated to AuNPs, a group of three B16 melanoma-bearing mice (blocking group, two tumors per mouse) was injected with an excess of unlabelled anti-CD105 mAbs (2 mg mAbs per mouse) 2 h before the injection of 89 Zr-anti-CD105-AuNPs-PPAA (3.6-4.1 MBq; total of 200 µg mAbs per mouse), as previously described [43] . The blocking group was compared with the group of mice who received only 89 Zr-anti-CD105-AuNPs-PPAA without a saturating dose.
Whole-body PET images were acquired using a dedicated small-animal PET scanner (MOSAIC; Philips Medical Systems, OH, USA) with an intrinsic spatial resolution of 2.5 mm (full width at half maximum) [44] . The PET scans were followed by whole-body acquisitions using a helical CT scanner (NanoSpect/ CT, Bioscan Inc., DC, USA) for anatomical reference. The PET/CT acquisitions were performed at different times after tracer injection (3, 6, 24, 48 and 72 h). All imaging procedures were performed under anesthesia with 1.5% isoflurane (Abbott Laboratories, Belgium)/ oxygen gas mixture (2 l min -1 ). Mice were maintained in a prone position on a heated animal bed at 37°C (Minerve, France). The PET acquisition durations were adapted to compensate for decay and ensure significant statistics (above 10,000 total counts). The emission scans were followed by transmission scans using a 370 MBq
137
Cs source for attenuation correction. All PET scans were reconstructed with a fully 3D iterative algorithm (3D-RAMLA) in a 128 × 128 × 120 matrix, with a voxel size of 1 mm³. After PET acquisition, the animal remained anesthetized and was transferred on the same bed from the PET scanner to the CT scanner (spatial resolution: 48 µm; x-ray tube voltage: 55 kVp; x-ray tube current: 145 µA; number of projections: 180; exposure time: 1000 ms). The CT projections were reconstructed with a voxel size of 0.221 × 0.221 × 0.221 mm³.
Before the PET and CT images were fused, the PET images were normalized according to a PET calibration factor including the positron branching ratio, the physical decay to the time of injection, the acquisition duration and the injected dose. This normalization was used to parameterize images in terms of percentage of the injected dose per ml. Regions of interest (ROIs) were delineated on the PET/CT fused images. The 2D ROIs were drawn on consecutive transversal slices using PMOD software (PMOD™, version 3.3, PMOD Technologies Ltd, Zurich, Switzerland), as previously described [34] . The tracer uptakes were assessed in the liver, lungs and tumors. Moreover, we defined a ROI, called background region, which was representative of tissues with low nonspecific uptake. The same background volume was drawn in the pelvic region of all animals, far from hot spots (organs with high uptake). The background signal was used to assess the specific-to-nonspecific tissue uptake, and particularly to estimate the tumor contrast, which was also expressed as tumor-to-background ratio, and which was calculated as the mean activity in the tumor region divided by the mean activity obtained in the background region. Finally, we quantified the blood activity over time by drawing ROIs within the ventricular cavity of heart, based on anatomical CT images fused with PET images (see Supplementary  Figure 1 online at http://www.future-medicine.com/ doi/full/10.2217/NNM.13.185).
Quantification of gold in tumors by ICP-MS
To compare the gold (Au) distribution of free nanoparticles to that of conjugated mAbs, two groups of four B16 melanoma-bearing mice were injected intravenously in the lateral tail vein with either freshly prepared AuNP-PPAA (a total of 36 µg Au per mouse) or with 89 Zr-anti-CD105-AuNPs-PPAA (a total of 18 µg Au per mouse, corresponding to 100 µg mAbs per mouse). Moreover, to confirm the in vivo specificity of anti-CD105 mAbs conjugated to AuNPs, a group of four B16 melanoma-bearing mice (blocking group) was injected with an excess of unlabeled anti-CD105 mAbs (2 mg mAbs per mouse) 2 h before the injection of anti-CD105-AuNPs-PPAA (a total of 22 µg Au per mouse, corresponding to a total of 200 µg mAbs per mouse). The blocking group was compared with the group of mice that received only anti-CD105-AuNPs-PPAA without a saturating dose. After 6 h, the animals were sacrificed. The blood and tumors were collected, weighed, freeze-dried and processed for gold content determination. The samples were hydrolyzed using 4 ml of pure 65% nitric acid (Merck Chemicals, Belgium) in a water bath at 60°C until complete solubilization of tissues. The analytical determination of gold ( 197 Au) in the samples was performed by inductively coupled plasma mass spectrometry (ICP-MS, type Agilent 7500cx, Agilent Technologies, Germany). The homogenized samples were diluted 100-times in a basic diluent (2% butanol, 0.05% EDTA, 1% NH 4 OH and 0.05% triton) containing iridium ( 193 Ir) as an internal standard. The Au content of the samples was quantified by plotting the calibration curve with known concentrations of an Au standard solution (Merck Chemicals, Belgium) used for the external calibration. The amount of Au detected in the tumors was expressed as a percentage of the injected dose and as a tumor-to-blood ratio.
Statistical ana lysis
Data calculations were performed with Prism software (Graph Pad™ Software Inc., version 5.02). The differences in tissue uptake of radioactivity between two groups were considered significant if the p-values from nonparametric two-tailed Mann-Whitney tests were ≤ 0.05 or ≤ 0.01. The differences in tissue uptake of radioactivity at different times were assessed by oneway ana lysis of variance and the Tukey post-hoc test. The differences in tissue uptake of Au between two groups were considered significant if the p-values from unpaired t-tests (two-tailed) were ≤ 0.05 or ≤ 0.01.
Results

Characterization of radioimmunoconjugates before & after nanoparticle conjugation
Df-Bz-NCS-anti-CD105 was radiolabelled with 89 Zr with a mean radiochemical yield of 49.7 ± 13.2% (n = 3), whereas the radiochemical purity immediately after purification was >95%. The resulting specific activity was 55.5 ± 14.3 MBq mg -1 of mAbs (n = 3). Electrophoresis of 89 Zr-labelled anti-CD105 mAbs under nonreducing conditions followed by radio-TLC and autoradiography showed a single band of 150 kDa corresponding to 89 Zr-Df-Bz-NCS-anti-CD105 and a single peak of radioactivity (see Supplementary  Figure 2A online at http://www.future-medicine. com/doi/full/10.2217/NNM.13.185), which means that the antibody integrity was preserved after the labelling reaction. Electrophoresis of antibody-labelled AuNPs under nonreducing conditions followed by radio-TLC showed a lower migration of 89 Zr-anti-CD105-AuNPs-PPAA compared with that of 89 Zr-Df-Bz-NCS-anti-CD105 and two peaks of radioactivity corresponding to the positions of the two species on the gel (see Supplementary Figure 2B online at http://www.future-medicine.com/doi/full/10.2217/ NNM.13.185). The percentage of radioactivity linked to the peak of 89 Zr-anti-CD105-AuNPs-PPAA expressed the coupling reaction yield, which was over 75%. The nanoparticle diameters observed by TEM imaging ranged from 3 to 10 nm (mean diameter: 4.8 ± 1.7 nm) [33] . The mean diameter of anti-CD105-AuNPs-PPAA was determined by differential centrifugal sedimentation and was estimated at approximately 102.6 ± 4.0 nm (Figure 1 ). This technique gives an 'apparent diameter', which may be affected by the non-perfect spherical shape of analyzed particle and by the nanoparticle coating. The size of anti-CD105-AuNPs-PPAA was not available through TEM imaging because the contrast was dominated by AuNPs, so that the nanoparticle coating was not visible. Moreover, it is likely that the carbodiimide reaction produces to some extent polymerized mAbs, which would increase the 'apparent diameter' of the conjugates. Finally, the in vitro stability of radioimmunoconjugates in plasma showed that 89 Zr was slightly dissociated from the antibody over time. Starting from a solution without free 89 Zr (100% purity), the percentages of dissociation were lower by 5% after 6 h, 10% after 24 h, and 15% after 48 and 72 h for both radioimmunoconjugates.
In vitro assessment of CD105 targeting
A cell-based ELISA study investigated the relative binding affinity of anti-CD105 mAbs towards endoglin-overexpressing cells before and after antibody conjugation to AuNPs. For this purpose, we chose the B16F10-luc melanoma cell line, known for its CD105 overexpression (CD105 + ) [14, 15] . The eEPC cell line was selected as negative control cells that do not express CD105, based on qualitative immunohistochem istry results and in vitro quantitative ELISA tests (data not shown). Different concentrations of anti-CD105 mAbs and anti-CD105-AuNPs-PPAA were tested on both CD105
+ and CD105 -cells (Figure 2 ). As expected, anti-CD105 mAbs bound to CD105 + cells in a concentration-dependent way, but not to CD105 -cells. Interestingly, anti-CD105-AuNPs-PPAA also bound to CD105
+ cells in a concentration-dependent manner, suggesting retention of the target recognition property after nanoparticle conjugation. The relative binding affinity of anti-CD105 mAbs before and after conjugation to AuNPs was quantified as a half-maximal effective concentration (EC 50 ). The EC 50 value was reduced from 1 µg ml -1 (for anti-CD105 mAbs) to 5 µg ml -1
(for anti-CD105-AuNPs-PPAA). The relative binding affinity remains on the same range (less than 1 log) before and after antibody conjugation to AuNPs. This lower CD105 binding affinity of conjugated antibody was confirmed in vivo by blocking experiments as described below.
PET evaluation of 89 Zr-labelled anti-CD105 mAbs biodistribution in mice before & after coupling reaction to AuNPs Two groups of B16 melanoma-bearing mice were injected with 89 Zr-Df-Bz-NCS-anti-CD105 or with 89 Zr-anti-CD105-AuNPs-PPAA, respectively. We then compared the pharmacokinetic behavior of 89 Zr-anti-CD105-AuNPs-PPAA with that of 89 Zr-Df-Bz-NCSanti-CD105, as a reference compound. Figure 3 shows repre sentative PET/CT images of mice bearing B16 tumor xenografts at different times after tracer injection (3, 6, 24, 48 and 72 h), and compares the distribution of 89 Zr-Df-Bz-NCS-anti-CD105 ( Figure 3A ) and 89 Zr-anti-CD105-AuNPs-PPAA (Figure 3B ), respectively. At the different times after injection, accumulation of the two tracers was predominantly observed in the liver (red arrows) and in tumors implanted in the legs (yellow arrows). The lung uptake (green arrows) was observed only at early times (3 and 6 h). A similar pattern was observed for both radioimmunoconjugates, but with visually higher liver, spleen and lung uptakes for 89 Zr-anti-CD105-AuNPs-PPAA than for 89 Zr-Df-Bz-NCS-anti-CD105 (Figure 3 ). This distribution pattern remained constant at later times for the liver and spleen. 3D videos representing PET/CT fusion MIP (maximum intensity projection) of mice that received 89 Zr-Df-Bz-NCS-anti-CD105 or 89 Zranti-CD105-AuNPs-PPAA are available online as Supplementary Materials 3 & 4, respectively (see online at http://www.future-medicine.com/doi/full/10.2217/ NNM.13.185).
For each time point considered, it must be mentioned that quantification of liver and lung uptakes showed no significant difference between the two groups (Figure 4) , despite the visually more pronounced tracer uptake observed on PET/CT images for 89 Zr-anti-CD105-AuNPs-PPAA compared with unconjugated antibody (Figure 3) . The liver and lung uptakes were fast, with maximum values observed 3 h after tracer injection. The maximum liver uptake was approximately 14.9 ± 2.8%ID ml -1 for 89 Zr-anti-CD105-AuNPs-PPAA and 11.7 ± 1.1%ID ml -1 for 89 Zr-Df-Bz-NCS-anti-CD105 (Figure 4A ), whereas the maximum lung uptake was approximately 15.2 ± 3.6%ID ml -1 for 89 Zr-anti-CD105-AuNPs-PPAA and 11.6 ± 1.0%ID ml -1 for 89 Zr-Df-Bz-NCS-anti-CD105)
( Figure 4B ).
The major differences between the biodistribution patterns were observed for tumor uptake ( Figure 5 ). In the tumor, the kinetics were relatively fast for both conjugated and unconjugated mAbs ( Figure 5A) , with a maximum uptake reached after 24 h, followed by a plateau phase (6.5 ± 0.4%ID ml -1 for 89 Zr-Df-Bz-NCS-anti-CD105 and 4.6 ± 0.1%ID ml -1 for 89 Zr-anti-CD105-AuNPs-PPAA). A decrease in tumor uptake was observed starting 24 h after injection in favor of unconjugated mAbs. However, a continuous increase in tumor-to-background ratio was observed over time, with no difference between the two groups ( Figure 5A) . Finally, the specificity of tumor uptake was investigated by administering a saturating dose of unlabeled anti-CD105 mAbs 2 h before 89 Zr-anti-CD105-AuNPs-PPAA injection. This saturation experiment showed that the CD105 binding of 89 Zr-anti-CD105-AuNPs-PPAA was markedly reduced in the tumor up to 24 h after injection (Figure 6 ). In fact, the residual activity in the tumor was significantly lower for the blocking group at 3, 6 and 24 h after injection compared with the tumor uptake in mice injected with only 89 Zr-anti-CD105-AuNPs-PPAA. The tumor uptake value in the blocking group 6 h after injection (1.9 ± 0.2%ID ml -1 ) was reduced by a factor of 2.5 compared with that for mice receiving only 89 Zr-anti-CD105-AuNPs-PPAA (4.7 ± 0.2%ID ml -1 ).
Assessment of Au content in tumors by ICP-MS
Au content was measured in blood and tumors by ICP-MS at 6 h after tracer injection. In the normal situation, the presence of Au is detectable without background in the body. Figure 7A shows that the amount of Au expressed as a percentage of the injected dose in tumors was significantly higher for mice receiving anti-CD105-AuNPs-PPAA (3.3 ± 0.4%ID) than for those 89 Zr-Df-Bz-NCS-anti-CD105 or (B) 89 Zr-anti-CD105-AuNPs-PPAA (one tumor per mouse). PET/CT images were obtained at different times after injection (3, 6, 24, 48 and 72 h). Color scale, expressed as a percentage of the injected dose per ml (%ID ml -1 ), indicated the radioactivity uptake levels in tumors (yellow arrows), in the liver (red arrows), in the spleen (orange arrows) and in the lungs (green arrows).
receiving AuNPs-PPAA (1.8 ± 0.1%ID). Moreover, the tumor-to-blood ratio was also significantly higher for the group of mice injected with anti-CD105-AuNPs-PPAA compared with the group of mice receiving free AuNPs ( Figure 7B ). The specificity of anti-CD105 mAbs after nanoparticle conjugation was confirmed by repeating the blocking experiment. The Au quantification in tumors after injecting a saturating dose of anti-CD105 mAbs 2 h before the anti-CD105-AuNPs-PPAA injection showed a significant decrease in Au content (1.3 ± 0.1%ID) compared with the group of mice receiving only anti-CD105-AuNPs-PPAA (3.3 ± 0.4%ID) at 6 h after injection ( Figure 7A ). The tumor-to-blood ratio values for the blocking group reached those for free nanoparticles and were significantly lower than those of mice receiving anti-CD105-AuNPs-PPAA without a prior saturating dose ( Figure 7B ).
Discussion
Because our group has recently developed a method for synthesizing AuNPs [41] and has successfully investigated the in vivo distribution of cetuximab conjugated to AuNPs [34] , we have expanded our studies of nanoparticle vectorization through conjugation to mAbs by choosing the anti-CD105 mAb, which is still little-known but seems to be promising for targeting tumor cells and angiogenic vascular endothelial cells. We combined the targeting properties of anti-CD105 mAbs and the favorable imaging properties of 89 Zr. Our major goal was to further characterize the in vivo distribution of these antibody-targeted AuNPs, with a focus on tumor targeting, and to assess the in vivo impact of nanoparticle conjugation on the antibody target recognition by using noninvasive PET imaging.
The biodistribution pattern of 89 Zr-anti-CD105-AuNPs-PPAA and that of 89 Zr-Df-Bz-NCS-anti-CD105 showed liver, spleen and lung uptakes (Figure 3) . First, the liver uptake quantification was not significantly different between the two groups ( Figure 4A ). It is known that one of the limitations of antibody-based imaging is the high background signal in the reticuloendothelial system (RES), which was particularly illustrated in our study by the liver uptake of the tracers. Furthermore, the large nanoparticles (100 nm) are not excreted in urine, which causes their extended presence in the circulation. Thus, the nanoparticles are eliminated from the blood by the RES and are accumulated in the spleen and liver [45] . On the other hand, the vascular endothelium structure of liver and spleen are discontinuous with large fenestrations, thus allowing nanomaterials (up to 100 nm) to pass through the endothelium and to be accumulated in these tissues [46] . Visually, the PET images showed that the liver uptake seemed to be increased after antibody conjugation to AuNPs (Figure 3) . The colloidal properties of AuNPs could be the cause of this effect.
The same finding was observed for the lungs. Visually, the PET images showed that the lung uptake seemed to be higher for 89 Zr-anti-CD105-AuNPs-PPAA than for 89 Zr-Df-Bz-NCS-anti-CD105 only at early times (3 and 6 h after injection) (Figure 3) . However, the lung uptake quantification showed no significant difference between the two groups at each time after injection ( Figure 4B ). First, no increase in lung accumulation was observed over time. The conjugates were cleared from lungs starting 24 h after injection. The alveolar macrophage activity of lungs might be the mechanism by which the conjugates were cleared [47] . The trans location of nanoparticles out of the lungs through lymphatic vessels was also described [48] . Further studies should be done to explore the lung clearance of our synthesized conjugates because the particle size, shape, surface properties and formulation affect the nano particle entrapment and the subsequent efficient uptake by macrophages [49] . Then, the constitutive expression of CD105 in vascularized organs like lungs may explain the lung uptake. Moreover, previous studies showed that high levels of CD105 expression are seen in the distal vessels of mouse lung [50] . Other studies described the size-dependent biodistribution of AuNPs and showed that nanoparticles sized 100 nm were only significantly deposited in the liver, spleen and blood [51] . Finally, our blocking experiments showed the decrease of the immunanoconjugate's uptake in lungs, liver and spleen for mice receiving a saturating dose of unlabelled mAbs (data not shown). However, we cannot exclude some aggregation of the conjugates in vivo after intravenous injection, which might increase the lung uptake without any obvious respiratory problem observed, such as pulmonary embolism. In this regard, special attention should be paid if these nanoconjugates are injected at higher doses, such as for therapeutic purposes.
It must be mentioned that no major accumulation of radioactivity was observed in nonspecific organs, aside from the liver, spleen and lungs, and to a lesser extent bones. Starting 24 h after injection, PET images displayed distinct hot spots in the joints (shoulders and knees) that might be assigned to the detachment of 89 Zr from the desferal moiety (Figure 3) . In fact, we observed that the two tracers were not fully stable under physiological conditions, with a release of up to 10% free 89 Zr being observed after 24 h of tracer incubation in plasma. Previous studies, including our latest study with cetuximab conjugated to AuNPs [34, 52] , reported a similar pattern of skeletal uptake and attributed the constant bone accumulation to the strong affinity of free 89 Zr ions for hydroxylapatite and phosphate constituents of bones. In fact, zirconium is known to bind to plasma proteins and it is later deposited in mineral bone [53] . Other studies hypothesized that high murine bone uptake is also due to the liver metabolism of the conjugate and the release of free 89 Zr into the circulation [54] .
With regard to tumor targeting, we observed that the tumor uptake expressed as %ID ml -1 was significantly decreased after nanoparticle conjugation, starting 1 day after injection. This decrease was confirmed by the results of an in vitro ELISA test. Nevertheless, the tumor-to-background ratio remained good, without a significant difference before and after nanoparticle conjugation. Thus, the preservation of high tumor contrast after nanoparticle conjugation supports the good imaging properties of these radioimmunonanoconjugates.
We compared current data with those obtained previously with cetuximab conjugated to AuNPs [34] . For 89 Zr-cetuximab-AuNPs-PPAA, the tumor uptake was not significantly lower than for 89 Zr-Df-Bz-NCS-cetuximab up to 72 h after injection, with preserved tumor contrast. Indeed, our previous studies showed that the in vitro binding activity of 89 Zr-cetuximab-AuNPs-PPAA (EC 50 value: 0.08 µg ml -1 ) was reduced by a factor of 2 compared with 89 Zr-Df-Bz-NCS-cetuximab (EC 50 value: 0.19 µg ml -1 ) [33] , while the EC 50 value of 89 Zr-anti-CD105-AuNPs-PPAA was approximately five-times lower than that of 89 Zr-Df-Bz-NCSanti-CD105. The larger size of conjugated anti-CD105 mAbs (100 nm) compared with that of conjugated cetuximab (30 nm) suggests a higher grafting rate of mAb molecules onto the nanoparticle surface (Figure 1) and might explain the observed decrease in tumor targeting ( Figure 5A ).
Despite the decrease in tumor uptake starting 1 day after injection, the maintained specificity of conjugated anti-CD105 mAbs was confirmed by an in vivo saturation experiment, suggesting the selective accumulation of 89 Zr-anti-CD105-AuNPs-PPAA in tumors and the preservation of the CD105 recognition property of the antibody after radiolabelling and coupling to AuNPs. In fact, the administration of unlabeled mAbs in excess before 89 Zr-anti-CD105-AuNPs-PPAA injection induced the saturation of CD105 binding sites and significantly decreased the CD105 binding of 89 Zr-anti-CD105-AuNPs-PPAA in tumors (Figure 6 ). These results confirmed antigen-specific binding and the partial preservation of antibody immunoreactivity.
On the other hand, ICP-MS ana lysis quantified the tumor uptake of functionalized AuNPs, functionalized AuNPs after a saturating dose of unlabelled anti-CD105 mAbs (blocking group) and free AuNPs, by determining the Au content at 6 h after injection ( Figure 7) . The significant decrease of Au content in tumors belonging to the blocking group compared with mice receiving anti-CD105-AuNPs-PPAA without saturating target receptors also confirmed the preservation of antibody specificity after nanoparticle conjugation, since the saturation of CD105 binding sites led to a significant decrease in Au in tumors ( Figure 7A) . Moreover, the significant higher amount of Au in tumors for mice receiving anti-CD105-AuNPs-PPAA compared with those receiving AuNPs-PPAA highlighted the improved tumor uptake of functionalized nanoparticles. Indeed, the presence of grafted mAbs on the nanoparticle surface might be favorable to directing the nanoimmunoconjugate to the tumor. These ligand-receptor interactions result in improved uptake of the nanocomplex into the tumor. Further studies are needed to assess the interest of active targeting by conjugating nanoparticles to nonspecific antibodies. Moreover, Figure 7B showed the significant higher tumor-to-blood ratio for mice injected with antibody-targeted nanoparticles compared with those receiving free AuNPs. This statement was supported by the significantly lower Au concentration in circulation for mice receiving anti-CD105-AuNPs-PPAA compared with that of mice receiving uncoupled nanoparticles (data not shown). This result is probably related to the greater uptake of anti-CD105-AuNPs-PPAA by the RES, as seen on PET images (Figure 3) .
This study highlights the potential of anti-CD105 antibody-labelled AuNPs in tumor detection and demonstrates the preservation of the antibody specificity after nanoparticle conjugation. Regarding cancer therapy, the anticancer effect of anti-CD105 mAbs due to their antiangiogenic properties might be boosted thanks to the photophysical properties of AuNPs. Indeed, previous studies have shown that AuNPs have interesting anticancer properties through photothermolysis of cancer cells and enhancement of the efficacy of radio therapy. It must be mentioned that a sufficient amount of Au delivered to tumors is required for these applications. For imaging purposes, as is the case for this study, we injected trace amounts of immunonanoconjugates, which are sufficient for diagnostic applications with a minimal risk of toxicity. However, we should consider increasing the amount of injected conjugates for therapeutic purposes [55] [56] [57] [58] and thus assessing the potential toxicity of high amounts of injected AuNPs. Furthermore, photo thermal therapy using visible laser is adequate for superficial tumors, such as melanoma, but not for deeper lesions, for which the short-wave radiofrequency field treatment is most suitable [59] . Finally, as it is possible to locally and specifically activate AuNPs accumulated in malignant tissues, the nonspecific uptake of immunonanoconjugates by the RES may be overcome thanks to the local radiation exposure of AuNPs. These encouraging results present new opportunities for nanoparticle-based drug delivery systems in future theranostic applications.
Conclusion & future perspective
Antibody-based targeting of angiogenesis represents a new promising diagnostic and therapeutic tool.
Among these tools, anti-CD105 mAbs have shown anticancer benefit in recent clinical studies [60] . Indeed, the proven value of endoglin as the most suitable marker for evaluating tumor angiogenesis [61, 62] has led to increasingly focused interest on CD105 as a target for immunoconjugates. On the other hand, AuNPs are the subject of intensive studies in biomedical applications. No studies have investigated the biomedical potential of anti-CD105 mAbs conjugated to AuNPs as immunonanocarriers for vascular targeting detection and therapy of cancer. Moreover, the development of more efficient drug delivery systems is important in effectively targeting cancer. For these reasons, we were interested in AuNPs as scaffolds to which anti-CD105 mAbs are attached as an attractive diagnostic and/or therapeutic tool. These immunonanoconjugates combine the therapeutic properties of anti-CD105 mAbs with those of AuNPs, and might improve antitumor efficacy. In this study, we have demonstrated that, despite decreased tumor uptake after nanoparticle conjugation, the in vivo antibody specificity and the tumor contrast in PET imaging are preserved. CD105-dependent tumor targeting was also confirmed by the quantification of Au in tumors. Thus, our studies validate anti-endoglin antibodyfunctionalized AuNPs as a new tool for diagnostic
Executive summary
Characterization of radioimmunoconjugates and in vitro assessment of CD105 targeting
• Anti-CD105 monoclonal antibodies (mAbs) conjugated to gold nanoparticles (AuNPs) were characterized in vitro in terms of size, plasmatic stability and binding to the target before in vivo experiments.
• The nanoparticle diameters observed by TEM imaging ranged from 3 to 10 nm. The mean diameter of anti-CD105 mAbs after coupling to AuNPs was estimated at approximately 102.6 ± 4.0 nm by differential centrifugal sedimentation.
• The in vitro stability in plasma of both radioimmunoconjugates showed that the percentages of dissociation were lower by 10% after 24 h. • The EC 50 value was reduced from 1 µg ml -1 (for anti-CD105 mAbs) to 5 µg ml -1 (for anti-CD105-AuNPs-PPAA). The relative binding affinity remains on the same range (less than 1 log) before and after antibody conjugation to AuNPs.
PET evaluation of 89 Zr-labelled anti-CD105 mAbs biodistribution in mice before and after coupling reaction to AuNPs
• The tumor uptake of 89 Zr-labelled anti-CD105 mAbs was quantified before and after nanoparticle conjugation using noninvasive PET imaging in mice. The decreased tumor uptake after conjugation reaction is in accordance with the results obtained with an in vitro ELISA study. Blocking experiments confirmed the specific tumor targeting of conjugated mAbs.
• The tumor-to-background ratio remained good after the conjugation reaction. The high tumor contrast after nanoparticle conjugation supports the good imaging properties of the radioimmunonanoconjugates.
• The tumor uptake of antibody-targeted AuNPs was also quantified using ICP-MS ana lysis by determining gold content in tumors, and was compared with the tumor uptake of free nanoparticles. Results highlighted the improved tumor uptake for functionalized nanoparticles. The specificity of anti-CD105 mAbs conjugated to AuNPs was confirmed through ICP-MS by repeating blocking experiments.
• No major accumulation of radioactivity was observed in nonspecific organs, aside from the liver, spleen and lungs, and to a lesser extent bones.
• These results present new opportunities for nanoparticle-based imaging and therapy systems in future theranostic applications.
and imaging of cancer. The nonspecific RES uptake of immunonanoconjugates could be a limitation in the use of radioactive nanoparticles for systemic meta bolic radiotherapy, but not for therapeutic strategies, such as photothermal therapy, where nanoparticle activation can be locally controlled. Overall, 89 Zr immuno-PET imaging is a powerful tool for characterizing the in vivo properties of such nanocomplex systems and can present new opportunities for drug delivery guided by in vivo imaging. These observations lay the groundwork for further theranostic applications and give further credence to the probability of future effective nanoparticle-based therapy systems. 
